Cargando…
Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection
OBJECTIVE: Antibody-dependent enhancement (ADE) affects host-virus dynamics in fundamentally different ways: i) enhancement of initial virus acquisition, and/or ii) increased disease progression/severity. Here we address the question whether anti-HIV-1 antibodies can enhance initial infection. While...
Autores principales: | Marasini, Bishal, Vyas, Hemant K., Lakhashe, Samir K., Hariraju, Dinesh, Akhtar, Akil, Ratcliffe, Sarah J., Ruprecht, Ruth M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631165/ https://www.ncbi.nlm.nih.gov/pubmed/34402452 http://dx.doi.org/10.1097/QAD.0000000000003050 |
Ejemplares similares
-
Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges
por: Gong, Siqi, et al.
Publicado: (2021) -
Mucosal Antibodies: Defending Epithelial Barriers against HIV-1 Invasion
por: Ruprecht, Ruth M., et al.
Publicado: (2019) -
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
por: Lakhashe, Samir K., et al.
Publicado: (2022) -
Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose
por: Sholukh, Anton M, et al.
Publicado: (2014) -
Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose
por: Sholukh, AM, et al.
Publicado: (2012)